Literature DB >> 8730099

Role of cyclin A and p27 in anti-IgM induced G1 growth arrest of murine B-cell lymphomas.

S A Ezhevsky1, H Toyoshima, T Hunter, D W Scott.   

Abstract

Cross-linking surface immunoglobulin (Ig)M on the WEHI-231 B-cell lymphoma results in decreased cell size, G1/S growth arrest, and finally DNA cleavage into oligonucleosomal fragments that are the classical features of apoptotic cells. Treatment of WEHI-231 cells with anti-IgM in early G1 phase prevents phosphorylation of the retinoblastoma gene product (pRb) and inhibits entry into S phase. Using unsynchronized cells, we previously demonstrated that cyclin A-associated and Cdk2-dependent GST-pRb kinase activity were inhibited in WEHI-231 cells treated with anti-IgM. We now show that progression of elutriated early G1 phase WEHI-231 cells from early into late G1 phase is accompanied by an increase in the abundance of cyclin A protein and cyclin A-associated kinase activity. Treatment of early G1 cells with anti-IgM prevented this increase in cyclin A-associated kinase activity at late G1, despite minimal changes in the overall level of cyclin A and Cdk2 proteins. Late G1 cells, which already possess high cyclin A-associated kinase activity, were insensitive to anti-IgM treatment and were able to complete the cell cycle. We also found that anti-IgM-treated cells contained increased amounts of the Cdk inhibitor protein p27Kip1. Essentially all of the cyclin A in treated cells was associated with p27, a result which we propose explains the lack of cyclin A/Cdk2 kinase activity. Accumulation of p27 in cyclin A kinase complexes, however, did not decrease the amount of Cdk2 bound to cyclin A. Thus, cross-linking IgM on growth-inhibitable B-cell lymphomas affects cyclin A kinase activity by increasing the levels of p27 in this complex, thus preventing productive pRb phosphorylation and leading to cell cycle arrest and subsequent apoptosis. These results are discussed in terms of the cell cycle restriction points that regulate lymphocyte function, as well as the lineage-specific differences in cell cycle control.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730099      PMCID: PMC275909          DOI: 10.1091/mbc.7.4.553

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  64 in total

1.  The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T.

Authors:  J W Ludlow; J Shon; J M Pipas; D M Livingston; J A DeCaprio
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

2.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element.

Authors:  J A DeCaprio; J W Ludlow; D Lynch; Y Furukawa; J Griffin; H Piwnica-Worms; C M Huang; D M Livingston
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

3.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.

Authors:  P L Chen; P Scully; J Y Shew; J Y Wang; W H Lee
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

4.  The retinoblastoma protein is phosphorylated during specific phases of the cell cycle.

Authors:  K Buchkovich; L A Duffy; E Harlow
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

5.  Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product.

Authors:  K Mihara; X R Cao; A Yen; S Chandler; B Driscoll; A L Murphree; A T'Ang; Y K Fung
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  Antigen receptor-induced cell cycle arrest in WEHI-231 B lymphoma cells depends on the duration of signaling before the G1 phase restriction point.

Authors:  D M Page; A L DeFranco
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Cell cycle-specific induction of Cdk2 expression in B lymphocytes following antigen receptor cross-linking.

Authors:  D A Tanguay; T C Chiles
Journal:  Mol Immunol       Date:  1994-06       Impact factor: 4.407

8.  Lymphoma models for B cell activation and tolerance. V. Anti-Ig mediated growth inhibition is reversed by phorbol myristate acetate but does not involve changes in cytosolic free calcium.

Authors:  D W Scott; D Livnat; J Whitin; S B Dillon; R Snyderman; C A Pennell
Journal:  J Mol Cell Immunol       Date:  1987

9.  Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes.

Authors:  E J Firpo; A Koff; M J Solomon; J M Roberts
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

10.  Lymphoma models for B cell activation and tolerance. III. Cell cycle dependence for negative signalling of WEHI-231 B lymphoma cells by anti-mu.

Authors:  D W Scott; D Livnat; C A Pennell; P Keng
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  9 in total

1.  Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

Authors:  P F Dijkers; R H Medema; C Pals; L Banerji; N S Thomas; E W Lam; B M Burgering; J A Raaijmakers; J W Lammers; L Koenderman; P J Coffer
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 2.  Cell cycle control mechanisms in B-1 and B-2 lymphoid subsets.

Authors:  Michael J Piatelli; Debra Tanguay; Thomas L Rothstein; Thomas C Chiles
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Spec-seq unveils transcriptional subpopulations of antibody-secreting cells following influenza vaccination.

Authors:  Karlynn E Neu; Jenna J Guthmiller; Min Huang; Jennifer La; Marcos C Vieira; Kangchon Kim; Nai-Ying Zheng; Mario Cortese; Micah E Tepora; Natalie J Hamel; Karla Thatcher Rojas; Carole Henry; Dustin Shaw; Charles L Dulberger; Bali Pulendran; Sarah Cobey; Aly A Khan; Patrick C Wilson
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

4.  Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index.

Authors:  M Sánchez-Beato; A I Sáez; J C Martínez-Montero; M Sol Mateo; L Sánchez-Verde; R Villuendas; G Troncone; M A Piris
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

5.  Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.

Authors:  W Rowan; J Tite; P Topley; S J Brett
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

6.  CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells.

Authors:  Chen-Feng Qi; Annica Martensson; Michela Mattioli; Riccardo Dalla-Favera; Victor V Lobanenkov; Herbert C Morse
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-10       Impact factor: 11.205

7.  Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells.

Authors:  M Wu; R E Bellas; J Shen; G E Sonenshein
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

8.  Interleukins 4 and 21 Protect Anti-IgM Induced Cell Death in Ramos B Cells: Implication for Autoimmune Diseases.

Authors:  Chin Wai Hui; Wai Chung Wu; Shui On Leung
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

9.  Cyclin-dependent kinase inhibitors and basement membrane interact to regulate breast epithelial cell differentiation and acinar morphogenesis.

Authors:  H A Coppock; D E Gilham; A Howell; R B Clarke
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.